Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole vs Standard Azole Prophylaxis in Neutropenia
NCT00044486Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2002
- Primary completion
- Dec 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of posaconazole in invasive fungal infection (IFI) (2 arms), sponsored by Merck & Co. Primary endpoint: Incidence of Proven or Probable Invasive Fungal Infections at 100 days. Started Jul 2002; status: completed.
02
Drugs
posaconazole
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT00044486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00044486.